{
    "Trade/Device Name(s)": [
        "Bigfoot Unity\u00ae Diabetes Management System"
    ],
    "Submitter Information": "Bigfoot Biomedical, Inc.",
    "510(k) Number": "K222280",
    "Predicate Device Reference 510(k) Number(s)": [
        "K202145"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QLG",
        "QOG"
    ],
    "Summary Letter Date": "March 1, 2023",
    "Summary Letter Received Date": "December 7, 2022",
    "Submission Date": "February 14, 2023",
    "Regulation Number(s)": [
        "21CFR862.1355",
        "21CFR880.5860"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System",
        "Factory Calibrated, Not For Use With Automated Insulin Delivery Systems"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Abbott FreeStyle Libre 2 Flash Glucose Monitoring sensor",
        "Mobile application",
        "Reusable insulin pen caps"
    ],
    "Method(s)/Technology(ies)": [
        "Continuous glucose monitoring",
        "Near field communication (NFC)",
        "Bluetooth"
    ],
    "Methodologies": [
        "Real-time glucose data measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Accessory",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for Bigfoot Unity\u00ae Diabetes Management System integrating continuous glucose monitoring with insulin dose recommendations using FreeStyle Libre 2 sensor and mobile app.",
    "Indications for Use Summary": "Indicated for the management of diabetes in persons age 12 years and older, providing glucose monitoring data and insulin dose information for users of disposable pen-injectors, intended for single patient use and requires a prescription.",
    "fda_folder": "Clinical Chemistry"
}